Capricor Therapeutics Completes Enrollment of Phase II Clinical Trial for Cenderitide to Treat Heart Failure
March 31, 2015 at 08:06 AM EDT
Capricor Therapeutics, Inc. (Nasdaq: CAPR), a biotechnology company focused on developing novel therapeutics for the treatment of ...